Anti-CD38 MAb, Lenalidomide Exposed, Pomalidomide+Dexamethasone (Pd), Daratumumab+Pomalidomide+Dexamethasone (DPd), Phase 3, 1,2,3,>=4 prior line of therapy, Relapsed Refractory Multiple Myeloma (RRMM)
### Instruction:
Identify the study with the following condition. 
### Input:
Anti-CD38 MAb, Lenalidomide Exposed, Pomalidomide+Dexamethasone (Pd), Daratumumab+Pomalidomide+Dexamethasone (DPd), Phase 3, 1,2,3,>=4 prior line of therapy, Relapsed Refractory Multiple Myeloma (RRMM) 
### Output:
Popular Name is APOLLO, Study ID is NCT03180736